Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue

Obesity

Volumn 18, Issue 5, 2010, Pages 926-931

  McLaughlin, Tracey M ^a   Liu, T ^b   Yee, Gail ^a   Abbasi, F ^a   Lamendola, C ^a   Reaven, G M ^a   Tsao, P ^a   Cushman, S W ^b   Sherman, A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PIOGLITAZONE;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOGENESIS; ADULT; AGED; ARTICLE; CELL COUNT; CELL SIZE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; OBESITY; PATHOLOGY; REGRESSION ANALYSIS; WAIST CIRCUMFERENCE;

ADIPOGENESIS; ADULT; AGED; BLOOD GLUCOSE; CELL COUNT; CELL SIZE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; OVERWEIGHT; REGRESSION ANALYSIS; SUBCUTANEOUS FAT, ABDOMINAL; THIAZOLIDINEDIONES; WAIST CIRCUMFERENCE;

RODENTIA;

EID: 77951666931     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.380     Document Type: Article

References (32)

1. McLaughlin T, Sherman A, Tsao P et al. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia 2007;50:1707-1715.
2. Danforth E Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 2000;26:13.
3. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-1669.
4. Boden G, Cheung P, Mozzoli M, Fried SK. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metab Clin Exp 2003;52:753-759.
5. Teranishi T, Ohara T, Maeda K et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metab Clin Exp 2007;56:1418-1424.
6. Hiragun A, Sato M, Mitsui H. Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent. J Cell Physiol 1988;134:124-130.
7. Sandouk T, Reda D, Hofmann C. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am J Physiol 1993;264:C1600-C1608.
8. Smith SR, Xie H, Baghian S, Needham A, McNeil M, Bogacka I, Bray GA: Pioglitazone changes the distribution of adipocyte size in type 2 diabetics. Adipocytes 2006; 2:11-22.
9. Ciaraldi T P, Kong A P, Chu NV et al. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 2002;51:30-36.
10. Shadid S, Jensen MD: Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003; 11:3148-3152.
11. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000;23:171-175.
12. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998;83:2773-2776.
13. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001;86: 3574-3578.
14. Pei D, Jones CN, Bhargava R, Chen YD, Reaven GM. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 1994;37:843-845.
15. Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970;49:2151-2160.
16. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981;30:387-392.
17. Hirsch J, Knittle JL. Cellularity of obese and nonobese human adipose tissue. Fed Proc 1970;29:1516-1521.
18. Jo J, Gavrilova O, Pack S, Jou W, Mullen S, Sumner AE, Cushman SW, Periwal V. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLoS Comput Biol 2009, 5:1-11.
19. de Souza CJ, Eckhardt M, Gagen K et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001;50:1863-1871.
20. Kolak M, Yki-Järvinen H, Kannisto K et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 2007;92:720-724.
21. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 2004;27:1660-1667.
22. Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 2005;48:96-104.
23. Adams M, Montague CT, Prins JB et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997;100:3149-3153.
24. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791.
25. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22:288-293.
26. Mori Y, Murakawa Y, Okada K et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999;22:908-912.
27. Kim SK, Hur KY, Kim HJ et al. The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. Eur J Endocrinol 2007;157:167-174.
28. Thomas EL, Potter E, Tosi I et al. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content. Atherosclerosis 2007;195:e181-e190.
29. Basu A, Jensen MD, McCann F et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006;29:510-514.
30. Smith SR, De Jonge L, Volaufova J et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metab Clin Exp 2005;54:24-32.
31. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003;26:3148-3152.
32. Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord 2004;28(Suppl 4):S12-S21